Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan:566:56-59.
doi: 10.1016/j.virol.2021.11.011. Epub 2021 Dec 1.

A two-dose optimum for recombinant S1 protein-based COVID-19 vaccination

Zhidong Hu  1 , Jian-Ping Chen  2 , Jin-Chuan Xu  1 , Zhen-Yan Chen  1 , Rong Qu  2 , Ling Zhang  2 , Wenrong Yao  2 , Juan Wu  1 , Heng Yang  1 , Douglas B Lowrie  1 , Yong Liu  3 , Xiao-Yong Fan  4
Affiliations

A two-dose optimum for recombinant S1 protein-based COVID-19 vaccination

Zhidong Hu et al. Virology. 2022 Jan.

Erratum in

Abstract

Background: Recombinant protein subunit vaccination is considered to be a safe, fast and reliable technique when combating emerging and re-emerging diseases such as coronavirus disease 2019 (COVID-19). Typically, such subunit vaccines require the addition of adjuvants to attain adequate immunogenicity. AS01, which contains adjuvants MPL and saponin QS21, is a liposome-based vaccine adjuvant system that is one of the leading candidates. However, the adjuvant effect of AS01 in COVID-19 vaccines is not well described yet.

Methods: In this study, we utilized a mixture of AS01 as the adjuvant for an S1 protein-based COVID-19 vaccine.

Results: The adjuvanted vaccine induced robust immunoglobulin G (IgG) binding antibody and virus-neutralizing antibody responses. Importantly, two doses induced similar levels of IgG binding antibody and neutralizing antibody responses compared with three doses and the antibody responses weakened only slightly over time up to six weeks after immunization.

Conclusion: These results suggested that two doses may be enough for a clinical vaccine strategy design using MPL & QS21 adjuvanted recombinant protein, especially in consideration of the limited production capacity of COVID-19 vaccine in a public health emergency.

Keywords: Adjuvant; COVID-19; Dose optimum; Protein vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
The optimization of dosage schedule. (A) The vaccination schedule. BALB/c mice were vaccinated intramuscularly with vaccines in groups of six as indicated, then the mice were sacrificed at 2 weeks after the final vaccination for assays of IgG binding antibody and neutralizing antibody responses. (B) The S1-specific antibody responses. (C) The neutralizing antibody titer. Data are shown as mean values (mean ± SD) for each group of six mice.
Fig. 2
Fig. 2
Duration of responses after two-dose vaccination. (A) The vaccination schedule. BALB/c mice were vaccinated intramuscularly with vaccines as indicated, then the mice were sacrificed at 2 weeks, 4 weeks, and 6 weeks after the final vaccination for assays of IgG binding antibody and neutralizing antibody responses. (B) S1-specific antibody responses. (C) The virus-neutralizing antibody titer. Data are shown as mean values (mean ± SD) for each group of six mice.
See this image and copyright information in PMC

References

    1. Arashkia A., Jalilvand S., Mohajel N., et al. Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: state of the art and future prospects. Rev. Med. Virol. 2020 - PMC - PubMed
    1. Baldwin S.L., Reese V.A., Larsen S.E., Beebe E., Guderian J., Orr M.T., et al. Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model. PLoS One. 2021;16(3) - PMC - PubMed
    1. Bouazzaoui A., Abdellatif A., Al-Allaf F.A., et al. Strategies for vaccination: conventional vaccine approaches versus new-generation strategies in combination with adjuvants. Pharmaceutics. 2021;13(2) - PMC - PubMed
    1. Didierlaurent A.M., Laupeze B., Di Pasquale A., et al. Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert Rev. Vaccines. 2017;16(1):55–63. - PubMed
    1. Huang W.C., Zhou S., He X., et al. SARS-CoV-2 RBD neutralizing antibody induction is enhanced by particulate vaccination. Adv. Mater. 2020;32(50) - PMC - PubMed

Publication types

MeSH terms